Inclusion Criteria:

- Male and female subjects between an age of 18 (or the legal age of consent in the
jurisdiction where the study is conducted) and 75 at the time of signing Informed
Consent Form (ICF).

2. Body Mass Index (BMI) of

1. ≥30 kg/m2

2. ≥27 kg/m2 and <30 kg/m2 with at least 1 of the following weight-related
comorbidities

- hypertension: on blood-pressure (BP)-lowering medication or having
systolic BP (SBP) ≥140 mmHg or diastolic BP (DBP) ≥90 mmHg at Screening

- dyslipidaemia: on lipid-lowering medication or having low-density
lipoprotein (LDL) ≥160 mg/dL (4.1 mmol/L) or triglycerides ≥150 mg/dL (1.7
mmol/L), or high-density lipoprotein (HDL) <40 mg/dL (1.0 mmol/L) for men
or HDL <50 mg/dL (1.3 mmol/L) for women at Screening

- cardiovascular disease (for example, ischemic cardiovascular disease, New
York Heart Association [NYHA] Functional Classification Class I-II heart
failure.)

- obstructive sleep apnoea (only in participants >30 years of age) 3. Stable
body weight for the 3 months prior to randomization (<5% body weight gain
and/or loss) 4. History of at least one self-reported unsuccessful dietary
effort to lose body weight 5. Fully vaccinated against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) during Coronavirus Disease
2019 (COVID-19) pandemic. Full Vaccination means having received all
recommended doses of a COVID-19 vaccine listed by either of World Health
Organization (WHO)-Emergency Use Listing (WHO-EUL), Food and Drug
Administration (FDA) or European Medicines Agency (EMA) or a mix and match
series composed of any heterologous combination of
WHO-EUL/FDA/EMA-approved or authorized COVID-19 vaccines. Alternatively, a
proven recovery from a COVID-19 infection in combination with at least one
vaccination with a WHO, FDA, EMA listed vaccine qualifies as a full
vaccination. The vaccination program must have been completed at least two
weeks prior ICF signed. For the avoidance of doubt, the vaccination scheme
received shall be in compliance with the current rules defined by the
relevant health authorities in the US or Europe.

6. Capable of giving signed informed consent, which includes compliance
with the requirements and restrictions listed in the ICF and in this
protocol

Exclusion Criteria:

-

1. Prior or planned surgical treatment for obesity (excluding liposuction or
abdominoplasty, if performed >1 year prior to screening) 2. Obesity induced by
other endocrinologic disorders (for example, Cushing's syndrome) or diagnosed
monogenetic or syndromic forms of obesity (for example, Melanocortin 4 Receptor
deficiency or Prader-Willi Syndrome) 3. Plan to have endoscopic and/or
device-based therapy for obesity or have had device removal within the last 12
months prior to screening including but not limited to

- mucosal ablation

- gastric artery embolization

- intragastric balloon

- duodenal-jejunal endoluminal liner. 4. Renal impairment measured as estimated
glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 during screening.

5. Any of the following: myocardial infarction, stroke, hospitalization for
unstable angina or transient ischaemic attack within the past 60 days
prior to screening 6. Subject presently classified as being in New York
Heart Association (NYHA) Class III and IV 7. Elevated resting pulse rate
(>100 bpm) at Screening and Visit 1 8. Electrocardiogram (ECG) considered
clinic ally significant by the Investigator at Screening 9. Known
clinically significant gastric emptying abnormalities (for example, severe
gastroparesis or gastric outlet obstruction), past gastric bypass
(bariatric) surgery or restrictive bariatric surgery (for example,
Lap-Band®), or chronic intake of drugs directly affecting gastrointestinal
(GI) motility 10. History or presence of acute or chronic pancreatitis.
11. History or presence of acute or chronic diverticulitis or
diverticulosis. 12. History or presence of a clinically significant active
autoimmune abnormality (for example, lupus or rheumatoid arthritis) 13.
History or presence of clinically significant gallbladder disease 14.
Signs and symptoms of any other liver disease other than non-alcoholic
fatty liver disease, or any of the following as determined during
screening

- Alanine aminotransferase (ALT) level >3.0X Upper limit of normal (ULN) for the
reference range

- Alkaline phosphatase (ALP) level >1.5X ULN for the reference range, or

- Total Bilirubin >1.5X ULN for the reference range (except for cases of known
Gilbert's Syndrome) 15. Evidence of hypothyroidism or hyperthyroidism based on
clinical evaluation and/or an abnormal thyroid-stimulating hormone that, in the
opinion of the Investigator, would pose a risk to patient safety. Subjects on a
stable dose of thyroid replacement therapy for at least the prior 3 months
before Visit 1 who are clinically euthyroid and who are anticipated to remain
on this dose throughout the trial period may be eligible if they meet the other
criteria 16. Known self or family history (first-degree relative) of multiple
endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or
medullary thyroid carcinoma 17. Eating habits consisting of eating relevant
amounts of food throughout the night (after 10 p.m.; except if working on night
shifts) 18. History or presence of bulimia or anorexia nervosa 19. History or
presence of significant active or unstable Major Depressive Disorder (MDD) or
other severe psychiatric disorder (for example, schizophrenia, bipolar
disorder, or other serious mood or anxiety disorder) within the last 2 years.

20. Lifetime history of suicide attempt 21. History of malignant neoplasms
within the past 5 years prior to screening. Basal and squamous cell skin
cancer and any carcinoma in-situ are allowed 22. Evidence of human
immunodeficiency virus (HIV) and/or positive HIV antibodies historically
or at Screening 23. Evidence of hepatitis B and/or positive hepatitis B
surface antigen. 24. Hepatitis C as defined by presence of positive
hepatitis C antibodies. 25. Unstable treatment with glucose-lowering
agent(s) within 90 days before Visit 1 26. Treatment with incretin mono-
or dual receptor agonists (e.g., Glucagon-like peptide 1 (GLP-1) or GLP-1/
Glucose-dependent insulinotropic polypeptide (GIP)) within 180 days prior
to screening and planned during the present study 27. Use of non-herbal
Chinese medicine or other non-herbal local medicine with
unknown/unspecified content within 90 days before screening 28. Surgery
scheduled for the duration of the trial, except for minor surgical
procedures, in the opinion of the investigator 29. Known or suspected
abuse of alcohol or recreational drugs 30. Illicit drug abuse (marihuana,
amphetamines, barbiturates, cocaine, opiates, phencyclidine and
benzodiazepines) 31. Known or suspected hypersensitivity to trial
product(s) or related products 32. Participation in another clinical trial
within 90 days before screening 33. Female who is pregnant, breast-feeding
or intends to become pregnant or is of child-bearing potential and not
using a highly effective contraceptive method 34. Any disorder,
unwillingness or inability, not covered by any of the other exclusion
criteria, which in the investigator's opinion, might jeopardize the
subject's safety or compliance with the protocol